The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
VelasquezW.S., CabanillasF., SalvadorP.Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ARA-C and dexamethasone (DHAP).Blood.1988; 71: 117–22.
2.
MartelliM., VignettiM., ZinzaniP.L.High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study.J Clin Oncol.1996; 14: 534–42.
3.
MartelliM., CiminoG., GastaldiR.DHAP treatment: Results of 18 patients with refractory or recurrent non-Hodgkin's lymphoma [letter].Haematologica.1990; 75: 194–5.
4.
WalewskiJ.A., Romejko-JarosinskaJ., ZwolinskiJ.DHAP chemotherapy for recurrent/refractory lymphoma – five year follow-up of 112 patients.Proc Am Soc Clin Oncol [CD-ROM version]. Abstract 1161. Alexandria, VA: American Society of Clinical Oncology; 2001.
5.
Rodriguez-MongeE.J., CabanillasF.Long-term follow-up of platinum-based lymphoma salvage regimens – the M.D. Anderson Cancer Center experience.Hematol Oncol Clin North Am.1997; 11: 937–47.
6.
National Comprehensive Cancer Network.NCCN non-Hodgkin's lymphoma practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version]. Rockledge, PA: National Comprehensive Cancer Network; 2001.
PhilipT., GuglielmiC., HagenbeekA.Autologous bone marrow transplantation compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.N Engl J Med.1995; 333: 1540–5.
9.
OlivieriA., OffidanaM., CinieroL.DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma.Bone Marrow Transplant.1995; 16: 85–93.
10.
PressO.W., LivingstonR., MortimerJ.Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation.J Clin Oncol.1991; 9: 423–31.
11.
ChauI., WebbA., CunninghamD.An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.Br J Hematol.2001; 115: 786–92.
12.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
13.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
14.
National Comprehensive Cancer Network (NCCN) antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version].Rockledge, PA: National Comprehensive Cancer Network; 2001.
15.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
16.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.Gynecol Oncol.1993; 50: 147–58.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000;18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34: 1857–64.
22.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6: 145–51.
23.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36: S15–S21.
24.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–9,63–7,70–4.
25.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49: 1796–9.
26.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–405.
27.
HigaG.M., GockermanJ.P., HuntA.L.The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.Cancer.1991; 68: 1691–3.
28.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
29.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–90.
